Coupled with previous demonstrations of efficacy of LXA4 and activation of LXA4 receptor in treatment of myocardial I/R injury [10], [11], our present results represent useful tools for the development of a new drug for treatment of ischemic heart diseases. The gene discussed is FPR2; the disease is coronary artery disorder.